Click here to go to the previous page
Radiotherapy and the Microenviornment; Molecular Radioprotection
Program Code:
PD09
Date:
Wednesday, November 4, 2009
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Dr. Joel S. Greenberger obtained the M.D. degree from Harvard Medical School in 1971 and completed Residency in Radiation Oncology in 1977. He was Staff Research Associate at the National Cancer Institute from 1972 1974 working in Viral Carcinogenesis. He has been Professor and Chairman of the Department of Radiation Oncology at the University of Pittsburgh since 1993 and has established a laboratory investigating the molecular mechanism of ionizing irradiation tissue damage and its amelioration by antioxidant gene therapy approaches. Since 1995, his research has focused on small molecule analogs of Manganese Superoxide Dismutase and other natural antioxidant enzymes. Small molecule radiation protectors and radiation damage mitigators (delivered after radiation exposure, but before clinical syndromes appear) appear to be an attractive alternative to transgene therapy, due to the ease of administration of small molecule targeted radioprotectors. The molecular mechanism of mitochondrial targeting and mitochondrial mechanisms of apoptosis serve as a second focus of research. Dr. Greenberger is author and co-author of over 300 publications on basic cellular and molecular biology as well as radiation biology and has recently authored multiple review articles on stem cell biology, stem cell involvement in radiation damage mitigation, and small molecule radiation modulating agents.
|
Sydney Evans, V.M.D., M.S., University of Pennsylvania School of Medicine